Regeneron and Telix Partner on $4.3B Radiopharmaceutical Co-Development

A 50/50 partnership worth up to $4.3B pairs Regeneron's antibody discovery platform with Telix's radiopharmaceutical manufacturing and global supply chain. The deal signals that biologics giants see targeted radiotherapy as the next frontier in oncology.